Out of these three receptors, we first focused on ACVR1, a Type I receptor that is expressed in a variety of cell types and plays key roles in bone and brain diseases (Agarwal et al., 2017; Shore et al., 2006; Valer et al., 2019), and asked whether reducing its expression could make ligand responses in NMuMG cells more similar to those of mESCs. This evidence concerns the gene SGCG and brain disorder.